SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis

NASDAQ:SUPN • US8684591089

54.73 USD
-1.02 (-1.83%)
At close: Feb 27, 2026
54.73 USD
0 (0%)
After Hours: 2/27/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to SUPN. SUPN was compared to 193 industry peers in the Pharmaceuticals industry. SUPN has only an average score on both its financial health and profitability. SUPN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • SUPN had positive earnings in the past year.
  • SUPN had a positive operating cash flow in the past year.
  • SUPN had positive earnings in 4 of the past 5 years.
  • SUPN had a positive operating cash flow in 4 of the past 5 years.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

1.2 Ratios

  • The Return On Assets of SUPN (-1.35%) is better than 76.68% of its industry peers.
  • SUPN has a Return On Equity of -1.82%. This is in the better half of the industry: SUPN outperforms 78.76% of its industry peers.
  • SUPN has a better Return On Invested Capital (2.87%) than 80.31% of its industry peers.
Industry RankSector Rank
ROA -1.35%
ROE -1.82%
ROIC 2.87%
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)N/A
ROIC(5y)N/A
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • The Operating Margin of SUPN (6.08%) is better than 80.83% of its industry peers.
  • SUPN's Gross Margin of 89.91% is amongst the best of the industry. SUPN outperforms 92.75% of its industry peers.
  • SUPN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.08%
PM (TTM) N/A
GM 89.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.02%
GM growth 5Y-0.06%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SUPN is destroying value.
  • The number of shares outstanding for SUPN has been increased compared to 1 year ago.
  • The number of shares outstanding for SUPN has been increased compared to 5 years ago.
  • SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 6.40 indicates that SUPN is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.40, SUPN belongs to the top of the industry, outperforming 80.83% of the companies in the same industry.
  • There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.4
ROIC/WACC0.31
WACC9.17%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.3 Liquidity

  • SUPN has a Current Ratio of 1.80. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of SUPN (1.80) is worse than 64.77% of its industry peers.
  • A Quick Ratio of 1.56 indicates that SUPN should not have too much problems paying its short term obligations.
  • SUPN has a Quick ratio (1.56) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.8
Quick Ratio 1.56
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.85%, which is quite good.
  • SUPN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.74% yearly.
  • Looking at the last year, SUPN shows a quite strong growth in Revenue. The Revenue has grown by 8.63% in the last year.
  • The Revenue has been growing slightly by 6.68% on average over the past years.
EPS 1Y (TTM)10.85%
EPS 3Y46.97%
EPS 5Y6.74%
EPS Q2Q%22.67%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.95% on average over the next years. This is quite good.
  • SUPN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.29% yearly.
EPS Next Y12.5%
EPS Next 2Y17.75%
EPS Next 3Y24.25%
EPS Next 5Y15.95%
Revenue Next Year22.15%
Revenue Next 2Y19.42%
Revenue Next 3Y18.15%
Revenue Next 5Y14.29%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 16.74 indicates a correct valuation of SUPN.
  • SUPN's Price/Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 86.53% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.07, SUPN is valued a bit cheaper.
  • Based on the Price/Forward Earnings ratio of 14.88, the valuation of SUPN can be described as correct.
  • Based on the Price/Forward Earnings ratio, SUPN is valued cheaper than 83.94% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.05, SUPN is valued a bit cheaper.
Industry RankSector Rank
PE 16.74
Fwd PE 14.88
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 80.83% of the companies in the same industry are more expensive than SUPN, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, SUPN is valued a bit cheaper than the industry average as 78.24% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 44.36
EV/EBITDA 21.5
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as SUPN's earnings are expected to grow with 24.25% in the coming years.
PEG (NY)1.34
PEG (5Y)2.48
EPS Next 2Y17.75%
EPS Next 3Y24.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SUPN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (2/27/2026, 8:00:00 PM)

After market: 54.73 0 (0%)

54.73

-1.02 (-1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners104.2%
Inst Owner Change-0.71%
Ins Owners4.26%
Ins Owner Change2.84%
Market Cap3.14B
Revenue(TTM)718.95M
Net Income(TTM)-19.12M
Analysts83.33
Price Target62.56 (14.31%)
Short Float %7.27%
Short Ratio6.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.78%
Min EPS beat(2)67.83%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)62.07%
Min EPS beat(4)15.55%
Max EPS beat(4)87.73%
EPS beat(8)7
Avg EPS beat(8)65.74%
EPS beat(12)9
Avg EPS beat(12)51.6%
EPS beat(16)10
Avg EPS beat(16)29.18%
Revenue beat(2)2
Avg Revenue beat(2)5.28%
Min Revenue beat(2)5.28%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)4.96%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.09%
Revenue beat(12)8
Avg Revenue beat(12)3.15%
Revenue beat(16)11
Avg Revenue beat(16)2.6%
PT rev (1m)0%
PT rev (3m)1.38%
EPS NQ rev (1m)-18.18%
EPS NQ rev (3m)40.26%
EPS NY rev (1m)-13.65%
EPS NY rev (3m)18.74%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)-1.39%
Revenue NY rev (1m)-1.32%
Revenue NY rev (3m)-0.55%
Valuation
Industry RankSector Rank
PE 16.74
Fwd PE 14.88
P/S 4.6
P/FCF 44.36
P/OCF 43.66
P/B 2.99
P/tB 10.22
EV/EBITDA 21.5
EPS(TTM)3.27
EY5.97%
EPS(NY)3.68
Fwd EY6.72%
FCF(TTM)1.23
FCFY2.25%
OCF(TTM)1.25
OCFY2.29%
SpS11.89
BVpS18.31
TBVpS5.36
PEG (NY)1.34
PEG (5Y)2.48
Graham Number36.7
Profitability
Industry RankSector Rank
ROA -1.35%
ROE -1.82%
ROCE 3.81%
ROIC 2.87%
ROICexc 3.87%
ROICexgc 47.85%
OM 6.08%
PM (TTM) N/A
GM 89.91%
FCFM 10.38%
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.02%
GM growth 5Y-0.06%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1.32%
Cap/Sales 0.16%
Interest Coverage 250
Cash Conversion 56.66%
Profit Quality N/A
Current Ratio 1.8
Quick Ratio 1.56
Altman-Z 6.4
F-Score5
WACC9.17%
ROIC/WACC0.31
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.85%
EPS 3Y46.97%
EPS 5Y6.74%
EPS Q2Q%22.67%
EPS Next Y12.5%
EPS Next 2Y17.75%
EPS Next 3Y24.25%
EPS Next 5Y15.95%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%
Revenue Next Year22.15%
Revenue Next 2Y19.42%
Revenue Next 3Y18.15%
Revenue Next 5Y14.29%
EBIT growth 1Y-47.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.43%
EBIT Next 3Y46.5%
EBIT Next 5Y27.36%
FCF growth 1Y-58.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.34%
OCF growth 3YN/A
OCF growth 5YN/A

SUPERNUS PHARMACEUTICALS INC / SUPN FAQ

Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to SUPN.


What is the valuation status for SUPN stock?

ChartMill assigns a valuation rating of 6 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.


What is the profitability of SUPN stock?

SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.


Can you provide the expected EPS growth for SUPN stock?

The Earnings per Share (EPS) of SUPERNUS PHARMACEUTICALS INC (SUPN) is expected to grow by 12.5% in the next year.